Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Vorozole

L R Wiseman1, C M Spencer

  • 1Adis International Limited, Auckland, New Zealand. demail@adis.co.nz

Drugs & Aging
|September 26, 1997
PubMed
Summary
This summary is machine-generated.

Vorozole effectively treats advanced breast cancer in postmenopausal women by inhibiting aromatase and reducing estradiol levels. Clinical trials show favorable efficacy and tolerability compared to other treatments.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Modafinil : A Review of its Pharmacology and Clinical Efficacy in the Management of Narcolepsy.

CNS drugs·2016
Same author

Quetiapine : A Review of its Use in Schizophrenia.

CNS drugs·2016
Same author

The Yin and Yang of inflammation.

Current molecular medicine·2014
Same author

Lymphotoxin beta receptor signaling limits mucosal damage through driving IL-23 production by epithelial cells.

Mucosal immunology·2014
Same author

Lanoteplase.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy·2007
Same author

Sdz asm 981.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy·2007
Same journal

Correction: Guideline-Directed Heart Failure Pharmacotherapy in Adults Aged ≥75 Years: Evidence Gaps, Tolerability, and Implications for Clinical Practice.

Drugs & aging·2026
Same journal

Targeted Treatment for Hyperuricemia: The Drug Pipeline.

Drugs & aging·2026
Same journal

Efficacy and Safety of Ciprofol Versus Propofol for Anesthesia in Older Patients: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.

Drugs & aging·2026
Same journal

Leveraging Real-World Data for Clinical Decision Making in Geriatric Oncology.

Drugs & aging·2026
Same journal

Drug Utilisation of Fall-Risk-Increasing Drugs (FRIDs) and Risk of Hospitalisation: A Nested Case-Control Study Among Community-Dwelling Older Adults.

Drugs & aging·2026
Same journal

Gabapentinoid Use and Risk of Alzheimer's Disease-Related Dementias: A Systematic Review and Meta-analysis of Observational Studies.

Drugs & aging·2026
See all related articles

Area of Science:

  • Endocrinology
  • Oncology
  • Pharmacology

Background:

  • Vorozole is a triazole derivative that inhibits the enzyme aromatase.
  • Aromatase inhibition leads to a significant reduction in plasma estradiol levels.
  • This mechanism is relevant for hormone-dependent conditions like breast cancer.

Purpose of the Study:

  • To evaluate the efficacy and tolerability of vorozole in postmenopausal women with advanced breast cancer.
  • To compare vorozole with established treatments such as aminoglutethimide and megestrol.
  • To assess the impact of vorozole on patients' quality of life.

Main Methods:

  • Phase II and Phase III clinical studies were conducted.
  • Vorozole was administered at a dose of 2.5 mg/day.

Related Experiment Videos

  • Efficacy and tolerability were assessed in comparison to aminoglutethimide and megestrol.

    • Main Results:

    • Vorozole achieved objective responses in up to 35% of patients in Phase II studies.
    • Phase III studies demonstrated favorable clinical efficacy for vorozole compared to aminoglutethimide and megestrol.
    • Vorozole showed improved quality of life and better tolerability than aminoglutethimide, and comparable tolerability to megestrol.

    Conclusions:

    • Vorozole is an effective treatment for postmenopausal women with advanced breast cancer.
    • Vorozole offers a favorable efficacy and tolerability profile compared to aminoglutethimide and megestrol.
    • Vorozole improves quality of life and is a viable therapeutic option for this patient population.